Published Date: 2021-01-06
Request a sample
According to the Graphical Research new growth forecast report titled “Europe Compounding Pharmacies Market Size By Therapeutic Area (Hormone Replacement, Pain Management, Dermatology Applications, Specialty Drugs, Nutritional Supplements), By Product (Oral {Solid Preparations [Tablets, Capsules, Granules, Powder], Liquid Preparations [Solutions, Suspension, Emulsion, Syrup], Topical [Ointments, Creams, Gels, Pastes], Rectal [Suppositories, Enema], Parenteral [LVP, SVP]}, Nasal, Ophthalmic, Otic), By Application (Pediatric, Adult, Geriatric, Veterinary), By Compounding Type (Pharmaceutical Ingredient Alteration [PIA], Currently Unavailable Pharmaceutical Manufacturing [CUPM], Pharmaceutical Dosage Alteration [PDA]), By Sterility (Sterile, Non-sterile), By Distribution Channel (Hospital Pharmacy, Compounding Pharmacy), Industry Analysis Report, Regional Outlook (Germany, UK, France, Italy, Spain, Poland, Ukraine, Greece, Sweden, Norway, Belgium, Czech Republic, Finland, Russia)”, Estimated To Surpass USD 3.1 Billion By 2026
Growing drug failure rate will escalate the compounding pharmacies market growth during the forecast period. UK government monitor drug developments that scrutinize the drugs on molecular level. Rising cases of low quality of drugs manufactured in UK will positively impact the compounding pharmacies industry growth in future. Increased drug failure rate decreases the availability of alternative medicines to patients resulting in increased dependence on compounding pharmacies to formulate required dosages, thereby accelerating the market growth.
The Europe compounding pharmacies market on the basis of therapeutic area is classified into specialty drugs, hormone replacement, nutritional supplements, pain management, and dermatology applications. The nutritional supplements segment is projected to witness around 3.3% CAGR over the projected timeframe. Nutritional supplements such as amino acids, vitamins and minerals, antioxidants or herbs are mixed at right dosage and format based on individuals’ needs. Compounded nutritional supplements avoids the unnecessary colors, fillers, and binders that are used in commercial product, surging its preference. Similarly, increasing number of compounding pharmacies in the European region that are developing customized nutritional supplements based on patient’s needs will favor the segmental progression.
The Europe compounding pharmacies market, based on product is fragmented into ophthalmic, nasal, rectal, otic, topical, oral, and parenteral. The parenteral segment accounted for more than USD 400 million market value in 2019. Parenteral compounding sterile preparations (CSPs) offer benefits such as rapid onset of action, and quick availability of drug to the body, enhancing the segmental growth. Parenteral CSPs also provide the advantage of localized delivery of drugs, as with intra-articular administration of corticosteroids in patients with rheumatoid arthritis that will foster the segmental growth.
The compounding pharmacies market, on the basis of application is classified into veterinary, pediatric, adult and geriatric. The pediatric segment accounted for more than 14.4% market share in 2019. Children majorly find it challenging to swallow tablets and at times commercially available preparations may not be palatable. Thus, children may opt for custom compounded prescriptions as pharmacists prepare sugar-free, flavored dosage forms based on children’s needs. Availability of various forms of customized medication for children include gummy treats, topical gels, effervescent drinks, oral liquids, enhancing the market growth.
Based on sterility, the Europe compounding pharmacies market is segmented into sterile and non-sterile. The sterile segment will witness around 5.5% CAGR during the analysis period. Rising incidence of chronic disorders including cancer and cardiac aliments will escalate the need for sterile medications, driving the compounding pharmacies market expansion. Growing demand for sterile compounding pharmacies owing to adoption of ophthalmic and parenteral medications for various treatments will spur the segmental growth.
The compounding pharmacies market, based on compounding type is classified into pharmaceutical dosage alteration (PDA), pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM) among others. The currently available pharmaceutical manufacturing (CUPM) segment held more than USD 500 million in 2019. Medications may be unavailable owing to variety of reasons including manufacturing problems, discontinuation of certain medications due to decreased usage and interruptions in supply chain. Growing number of chronic diseases requiring emergency medications coupled with rising drug shortages will support the segmental market growth.
Based on the distribution channel, the Europe compounding pharmacies market is fragmented into hospital pharmacy, compounding pharmacies and others. Amongst them, the hospital pharmacy segment is projected to witness more than 52% market share in 2019. Rising demand for custom medication from hospital admitted patients coupled with high patient volume in hospitals will spur the segment growth. Increasing number of chronic diseases requiring personalized medicine for treatment at hospitals will surge the segment demand.
UK compounding pharmacies market is projected to witness around 5% CAGR during the forecast period. Increasing demand for compounded medications will positively influence the market growth. Rising income level in developed economies including UK will boost the regional growth. The shortage of drugs across the country has stimulated compounded pharmacists to fill in the gap, thereby increasing its adoption rate. Also, dedicated efforts by the compounding pharmacists’ community for preparing effective customized medication will propel the country growth.
Some of the foremost industry players operating in the Europe compounding pharmacies market are B. Braun, Fagron, Nova Laboratories, Specialist Pharmacy, Baxter, Fresenius Kabi, McKesson Corporation, Athenex Pharma Solutions, Clinigen Group, and Galenic Laboratories. These prominent market players are focusing on developing inorganic and organic growth strategies for maintaining financial stability in the compounding pharmacies market. For instance, in August 2018, Athenex Pharma Solutions developed compounded vasopressin injection in ready-to-use premix intravenous bags. This new product launch assisted the firm expand their product portfolio.
Europe compounding pharmacies market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2015 to 2026, for the following segments:
Compounding Pharmacies Market, By Therapeutic Area, 2015 - 2026 (USD Million)
Europe Compounding Pharmacies Market, By Product, 2015 - 2026 (USD Million)
Europe Compounding Pharmacies Market, By Application, 2015 - 2026 (USD Million)
Compounding Pharmacies Market, By Compounding Type, 2015 - 2026 (USD Million)
Europe Compounding Pharmacies Market, By Sterility, 2015 - 2026 (USD Million)
Europe Compounding Pharmacies Market, By Distribution Channel, 2015 - 2026 (USD Million)
The above information is provided for the following region and countries:
The great explorer of the truth, the master-builder of human happiness no one rejects dislikes avoids pleasure itself because it is pleasure but because know who do not those how to pursue pleasures rationally encounter consequences that are extremely painful desires to obtain.
Read More